Other Specialties
39 videos · last 6 months shuffled daily, then older videos newest first
▶
56:23 Psychedelics for IBS: Inside the First Clinical Trial with Erin Mauney, MD
Dr. Erin Mauney, a pediatric gastroenterologist and researcher at Harvard and Massachusetts General Hospital, on one of the first clinical trials of psilocybin-assisted therapy for patients with treatment-resistant IBS.
▶
6:20 MONVISO: Etentamig Efficacy by Prior BCMA Therapy
Saurabh Chhabra, MBBS, MS, of Mayo Clinic Arizona describes how efficacy of etentamig, a BCMA x CD3 bispecific, varied by prior BCMA-targeting therapy in the phase 1b MONVISO study presented at ASCO 2026, for Blood Cancers Today.
▶
1:26 Iberdomide FDA Approval and the Next CELMoDs in Myeloma
Sagar Lonial, MD, discusses the FDA approval of iberdomide for multiple myeloma and the CELMoD trials to watch next, including mezigdomide in the phase 3 SUCCESSOR-2 trial, at the 2026 International Myeloma Society meeting, for Targeted Oncology.
▶
10:06 Proteomic Aging Clocks in a Phase 2a Trial
Fedor Galkin, Director of Longevity AI Research at Insilico Medicine, walks through the company's Nature Biotechnology paper applying proteomic aging clocks to data from a Phase 2a clinical trial.
▶
4:17 Wearable Monitor for Postpartum Bleeding in Global Study
InvestigateTV reports that Woman's Hospital is testing Baymatob's Oli wearable monitor, designed to detect warning signs of postpartum hemorrhage, as one of the first US hospitals in a global study of the device.
▶
2:18:22 Gerotherapeutic Regulatory Constructs: Morning Session
In the morning session of a Reagan-Udall Foundation for the FDA public meeting with ARPA-H and XPRIZE, speakers cover what ageing trials have taught about endpoints, populations and feasibility, and multi-domain endpoints for gerotherapeutics.
▶
2:48:26 Gerotherapeutic Regulatory Constructs: Afternoon Session
The Reagan-Udall Foundation for the FDA, with ARPA-H and the XPRIZE Foundation, holds a public meeting on regulatory pathways for gerotherapeutic drugs, biologics and devices, including industry views on what sponsors need from FDA.
▶
51:58 REMAP-CAP Results Oseltamivir in Critically Ill Influenza Patients
Dr. Srinivas Murthy, Dr. Thomas Hills and Dr. Lindsay Berry discuss on Berry Consultants' In the Interim podcast the REMAP-CAP results finding oseltamivir did not reduce 90-day mortality in critically ill influenza patients.
▶
13:27 Prader-Willi Syndrome: Diazoxide Choline Extended Release Improves Hyperphagia
Evelien Gevers, PhD, MD, of Barts Health NHS Trust on the effect of diazoxide choline extended release on hyperphagia in patients with Prader-Willi syndrome.
▶
30:58 CAR-T for NMOSD: A Phase 1 Trial
Dr. Michael Levy and Dr. Benjamin Greenberg describe for SRNA an autologous Phase 1 CAR-T study in aquaporin-4-positive NMOSD at Mass General and UT Southwestern, covering eligibility, risks and lessons for neuroimmune research.
▶
23:32 NF Summit 2026: Partners in Discovery - How Patients Help Advance NF2-SWN Research
Olena Bracho, MBA, of the University of Miami on how patients contribute directly to NF2-SWN research, presented at the NF Summit 2026.
▶
3:04 Mobile Health App Study in Youth With Prediabetes
Talia Hitt, a pediatric endocrinologist at Johns Hopkins Children's Center, discusses her study in which participants aged 13 to 17 with prediabetes used the Prosper mobile health app for lifestyle modification.
▶
56:34 Luxa's RPE Stem Cell Therapy: Phase 1 Trial in AMD
Dr. Jeffrey Stern, co-founder of the Neural Stem Cell Institute and co-CEO of Luxa Biotechnology, discusses its stem cell-derived RPE therapy, early results from a first-in-human Phase 1 trial in late-stage AMD and plans to include inherited retinal disease.
▶
44:40 Who Clinical Trials Left Out, and Why It Matters
Pediatrician Dr. Kerry Sease and health equity researcher Dr. Shaniece Criss discuss why women, children and people of color were often left out of clinical trials and how that gap still affects drug dosing and device accuracy, for FOX Carolina News.
▶
7:19:47 Testosterone Use in Menopausal Women
The FDA Office of Women's Health and Center for Drug Evaluation and Research hold a public hybrid workshop on testosterone use in menopausal women.
▶
3:27 Gene Therapy Weekly: FOXG1's First Trial Site Is Open
GENEration Hope reports that the FOXG1 gene therapy trial has activated its first clinical site, at Texas Children's Hospital and Baylor College of Medicine.
▶
3:45 Pediatric Fracture Care: The COMET and DRIFT Trials
Johns Hopkins pediatric orthopaedic surgeon R. Jay Lee, M.D., discusses the multicenter randomized COMET and DRIFT trials, which compare treatment approaches for elbow and wrist fractures in children.
▶
23:17 Alex Zhavoronkov on AI Drug Discovery at the Nature Conference
Insilico Medicine founder and CEO Alex Zhavoronkov describes the company's AI-driven drug discovery model, the advance of rentosertib into Phase III and a Phase IIa study using proteomic aging clocks, at a Nature Conference in Paris.
▶
56:22 SODa-BIC: Bicarbonate in Critically Ill Patients
Prof. Ary Serpa Neto of Austin Hospital and Monash University and Prof. Boris Jung of CHU Montpellier, PI of the BICAR-ICU trials, discuss the SODa-BIC trial of bicarbonate for metabolic acidosis in critically ill patients, published in the NEJM in June 2026.
▶
6:53 IBEX Study: Iberdomide Plus Daratumumab Myeloma Maintenance
Jeffrey Zonder, MD, of Karmanos Cancer Institute discusses first results from the IBEX study of iberdomide plus subcutaneous daratumumab as maintenance after stem cell transplant, including side effects and MRD responses, at IMS 2026.
▶
36:20 Rethinking Child Assent Practices in Research
Dr. David Coker discusses rethinking child assent in research beyond procedural compliance, including regulatory tensions, inclusion of children with disabilities and the role of IRBs, on CITI Program's On Research podcast.
▶
36:39 Rethinking Trial Design for Rare Diseases
Kim Kushner and Ramin Farhood speak with Marshall Summar, CEO and founder of Uncommon Cures, who has run more than 200 rare disease trials, about rethinking trial design for rare diseases.
▶
2:12 Freedom from Immunosuppression for Kidney Transplant Patients at Mayo
Mayo Clinic looks at an ongoing living donor kidney transplant clinical trial.
▶
59:30 Kaftrio and the CFTR Modulator Trials in Cystic Fibrosis
Dr Ian Balfour-Lynn, consultant in paediatric respiratory medicine at the Royal Brompton Hospital, reviews the clinical trials that led to licensing of CFTR modulators such as Kaftrio and real-world experience with them, for the Genomics Education Programme.